← boardnext 2026-10-31next 2026-11-30next 2026-12next 2027-05
VTRS
Viatris Innovation GmbHdistress 2/10 · well-funded / low risk$16.82-1%today-4% from 52w high
Lead: Lupus Erythematosus · est. market ~$5B (approx, global)
Revenue
$3517M
Liquidity
$1804M
Runway
—
Shares 1y
0%
Price & events
+29.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.1%
1D
-2.9%
1W
+6.8%
1M
+14.9%
3M
+29.4%
6M
+86.6%
1Y
+59.3%
2Y
+49.2%
5Y
+12.8%
All
Overview
- Market Cap
- $19.59B
- Enterprise Value
- $30.20B
- Volume
- 402.29K
- 52 Week Range
- $8.74 – $17.59
- Total Shares
- 1.16B
- Float Shares
- 1.16B
- Short %
- 4.13%
- % Held by Insiders
- 0.31%
- % Held by Institutions
- 88.24%
- RVOL
- 0.04x
- Beta
- 0.90
Pipeline stages · 4 programs
Cenerimod
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Selatogrel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Transdermal system containing progestin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 8 trials · 8 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-10-31 Estimated 50% readout ~2027-01-14 | Phase 3 | Cenerimod | Lupus Erythematosus, Systemic | — | active not recruiting |
| 2026-10-31 Estimated 50% readout ~2027-01-14 | Phase 3 | Cenerimod | Lupus Erythematosus, Systemic | — | active not recruiting |
| 2026-11-30 Estimated 50% readout ~2027-01-14 | Phase 2 | MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN) | Contraception | — | recruiting |
| 2026-12 Estimated 50% readout ~2027-02-14 | Phase 3 | Selatogrel | Acute Myocardial Infarction | — | enrolling by invitation |
| 2027-05 Estimated 50% readout ~2027-07-15 | Phase 3 | Transdermal system containing progestin | Female Contraception | — | active not recruiting |
Show all 8 trials · 3 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-10-08 Estimated 50% readout ~2027-11-22 | Phase 2 | cenerimod 4 mg | SLE - Systemic Lupus Erythematosus | — | active not recruiting |
| 2028-05 Estimated 50% readout ~2028-07-15 | Phase 3 | Cenerimod | Lupus Erythematosus, Systemic | — | enrolling by invitation |
| 2029-08 Estimated 50% readout ~2029-10-15 | Phase 3 | Cenerimod | Nephritis, Lupus, Lupus Erythematosus, Systemic | — | recruiting |
Catalyst news & presentations · 2
- 2026-08-06Confirmed 100%earningsEarningsEarnings releaseyahoo
- 2025-12-06partnershipAgreement to sell equity stake in Biocon Biologics for $400M cash and $415M Biocon shares; non-compete expires Q1 2026 ex-U.S., November 2026 U.S.SEC 8-K
Approved drugs (14)
- TOBI PODHALERTOBRAMYCIN2013 · Prescription
- REVATIOSILDENAFIL CITRATE2012 · Discontinued
- REVATIOSILDENAFIL CITRATE2009 · Prescription
- EDLUARZOLPIDEM TARTRATE2009 · Prescription
- ASTEPROAZELASTINE HYDROCHLORIDE2008 · Discontinued
- ELESTRINESTRADIOL2006 · Prescription
- REVATIOSILDENAFIL CITRATE2005 · Prescription
- CARDURA XLDOXAZOSIN MESYLATE2005 · Prescription
- GEODONZIPRASIDONE MESYLATE2002 · Prescription
- NITROSTATNITROGLYCERIN2000 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $18 (+6% upside) · 8 analysts
- 2026-05-19BarclaysOverweight
- 2026-05-08JP MorganNeutral
- 2026-05-08Truist SecuritiesBuy
- 2026-03-24BarclaysOverweight
- 2026-01-28Piper SandlerNeutral
- 2026-01-16Argus ResearchHold → Buy
Competitors — Lupus Erythematosus
- ABBVAbbVie Inc.$451.1B · D2
- NVSEFNOVARTIS AG$292.0B · D3
- BIIBBIOGEN INC.$29.2B · D2
- ZBIOZenas BioPharma, Inc.$2.0B · D3
- CGEMCullinan Therapeutics, Inc.$1.1B · D1
- AUTLAutolus Therapeutics plc$378M · D8
- FATEFATE THERAPEUTICS INC$294M · D3
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
- ACETAdicet Bio, Inc.$78M · D5
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-22Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch
- 2026-07-22Viatris’ Quarterly Earnings Preview: What You Need to Know - Inkl
- 2026-07-21Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
- 2026-07-20Viatris Inc. stock falls Monday, underperforms market - MarketWatch
- 2026-07-18Khaitan & Co Advised Viatris Inc. On Secondary Sale Of Shares Held in Biocon - BW Legal World
- 2026-07-18Is Viatris (VTRS) Reframing Its Musculoskeletal Strategy Through the AAOS Pain Management Partnership? - Sahm
- 2026-07-17Viatris stock hits 52-week high at $17.54 - Investing.com
- 2026-07-16Viatris Inc (VTRS) Stock Up 3.8% but GF Value Says Overvalued -- GF Score: 58/100 - GuruFocus
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.